Monopar Therapeutics Reports Strong Financials and Mid-2026 NDA Plan for Lead Drug ALXN1840

summarizeSummary

Monopar Therapeutics announced robust Q4 and full-year 2025 financial results, including a $140.4 million cash position providing a runway through December 2027, and confirmed plans for a mid-2026 NDA submission for its lead Wilson disease candidate, ALXN1840.

check_boxKey Events

• Strong Cash Position & Extended Runway

  Reported $140.4 million in cash, cash equivalents, and short-term investments as of December 31, 2025, providing an operational runway through at least December 31, 2027.

• ALXN1840 NDA Submission Planned

  Confirmed plans to submit a New Drug Application (NDA) for ALXN1840 in Wilson disease to the FDA in mid-2026, following positive interactions with the agency.

• Reduced Net Loss

  Reported a net loss of $13.7 million for the full year 2025, a decrease from $15.6 million in 2024.

• Pipeline Advancement

  Provided updates on ALXN1840's positive long-term efficacy and safety data presentations, and progress in MNPR-101 radiopharmaceutical programs, including IND clearance for a US Phase 1 trial.

auto_awesomeAnalysis

This filing provides a highly positive update for Monopar Therapeutics, highlighting a substantial cash position of $140.4 million, which is expected to fund operations through at least December 2027. This significantly de-risks the company's financial outlook. Furthermore, the company's lead candidate, ALXN1840 for Wilson disease, is on track for a New Drug Application (NDA) submission in mid-2026, representing a critical regulatory milestone. The progress across its radiopharmaceutical programs and the strategic strengthening of the leadership team for potential commercialization further underscore the company's advancement. Investors should monitor the upcoming NDA submission and continued clinical progress.